Cargando…

Late somatic sequelae after treatment of childhood cancer in Slovenia

BACKGROUND: This is a long-term follow-up clinical study of adolescents and adults, survivors of childhood cancer. We evaluate and analyze the late somatic sequelae of childhood cancer treatment. Many such studies are susceptible to a strong selection bias, i.e., they employ a limited non-systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Erman, Nuša, Todorovski, Ljupčo, Jereb, Berta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444361/
https://www.ncbi.nlm.nih.gov/pubmed/22624861
http://dx.doi.org/10.1186/1756-0500-5-254
_version_ 1782243668489404416
author Erman, Nuša
Todorovski, Ljupčo
Jereb, Berta
author_facet Erman, Nuša
Todorovski, Ljupčo
Jereb, Berta
author_sort Erman, Nuša
collection PubMed
description BACKGROUND: This is a long-term follow-up clinical study of adolescents and adults, survivors of childhood cancer. We evaluate and analyze the late somatic sequelae of childhood cancer treatment. Many such studies are susceptible to a strong selection bias, i.e., they employ a limited non-systematic sample of patients, based on a clinical hospital that provided the cancer treatment or performed the follow-up. To address the issue of selection bias, we perform here an analysis of late sequelae on a systematic database of the entire population of the children treated for cancer in Slovenia. Due to the specifics of cancer treatment procedures in Slovenia, they have all been treated and followed-up in the same clinic. METHODS: The data are based on the centralized registry of cancer patients in Slovenia and present a controlled and homogeneous collection. Late sequelae are evaluated following a modified CTCAE, i.e., the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 3.0. We use survival analysis method to estimate the incidence of and risk for late sequelae, where the time variable is measured in years from the diagnosis date, while we follow the event of incidence of late sequelae scored other than none. Survival analysis is performed using KaplanMeier estimator and Cox regression model. RESULTS: The incidence of mild, moderate, or severe late sequelae of childhood cancer treatment significantly decreased from 75% in the group of patients diagnosed before 1975 to 55% for those diagnosed after 1995. The Cox regression analysis of the risk factors for the incidence of late sequelae identifies three significant factors: treatment modalities, age at diagnosis, and primary diagnosis. CONCLUSIONS: The change of treatment modalities in terms of replacement of surgery and radiotherapy with chemotherapy is the main reason for the decrease of the incidence and the risk for late sequelae of childhood cancer treatment; treatment modalities including surgery significantly increase the risk ratio of late sequelae, while those based on chemotherapy only significantly decreases the risk. Risk of late sequelae increases with the diagnosis age: younger children are more susceptible to late effects of treatment. Finally, primary diagnosis significantly influences the risk for late sequelae, but mostly due to the dependency of the treatment modality on the primary diagnosis.
format Online
Article
Text
id pubmed-3444361
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34443612012-09-18 Late somatic sequelae after treatment of childhood cancer in Slovenia Erman, Nuša Todorovski, Ljupčo Jereb, Berta BMC Res Notes Research Article BACKGROUND: This is a long-term follow-up clinical study of adolescents and adults, survivors of childhood cancer. We evaluate and analyze the late somatic sequelae of childhood cancer treatment. Many such studies are susceptible to a strong selection bias, i.e., they employ a limited non-systematic sample of patients, based on a clinical hospital that provided the cancer treatment or performed the follow-up. To address the issue of selection bias, we perform here an analysis of late sequelae on a systematic database of the entire population of the children treated for cancer in Slovenia. Due to the specifics of cancer treatment procedures in Slovenia, they have all been treated and followed-up in the same clinic. METHODS: The data are based on the centralized registry of cancer patients in Slovenia and present a controlled and homogeneous collection. Late sequelae are evaluated following a modified CTCAE, i.e., the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 3.0. We use survival analysis method to estimate the incidence of and risk for late sequelae, where the time variable is measured in years from the diagnosis date, while we follow the event of incidence of late sequelae scored other than none. Survival analysis is performed using KaplanMeier estimator and Cox regression model. RESULTS: The incidence of mild, moderate, or severe late sequelae of childhood cancer treatment significantly decreased from 75% in the group of patients diagnosed before 1975 to 55% for those diagnosed after 1995. The Cox regression analysis of the risk factors for the incidence of late sequelae identifies three significant factors: treatment modalities, age at diagnosis, and primary diagnosis. CONCLUSIONS: The change of treatment modalities in terms of replacement of surgery and radiotherapy with chemotherapy is the main reason for the decrease of the incidence and the risk for late sequelae of childhood cancer treatment; treatment modalities including surgery significantly increase the risk ratio of late sequelae, while those based on chemotherapy only significantly decreases the risk. Risk of late sequelae increases with the diagnosis age: younger children are more susceptible to late effects of treatment. Finally, primary diagnosis significantly influences the risk for late sequelae, but mostly due to the dependency of the treatment modality on the primary diagnosis. BioMed Central 2012-05-24 /pmc/articles/PMC3444361/ /pubmed/22624861 http://dx.doi.org/10.1186/1756-0500-5-254 Text en Copyright ©2012 Erman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Erman, Nuša
Todorovski, Ljupčo
Jereb, Berta
Late somatic sequelae after treatment of childhood cancer in Slovenia
title Late somatic sequelae after treatment of childhood cancer in Slovenia
title_full Late somatic sequelae after treatment of childhood cancer in Slovenia
title_fullStr Late somatic sequelae after treatment of childhood cancer in Slovenia
title_full_unstemmed Late somatic sequelae after treatment of childhood cancer in Slovenia
title_short Late somatic sequelae after treatment of childhood cancer in Slovenia
title_sort late somatic sequelae after treatment of childhood cancer in slovenia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444361/
https://www.ncbi.nlm.nih.gov/pubmed/22624861
http://dx.doi.org/10.1186/1756-0500-5-254
work_keys_str_mv AT ermannusa latesomaticsequelaeaftertreatmentofchildhoodcancerinslovenia
AT todorovskiljupco latesomaticsequelaeaftertreatmentofchildhoodcancerinslovenia
AT jerebberta latesomaticsequelaeaftertreatmentofchildhoodcancerinslovenia